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2 
Summary 26 
Human adenovirus type 5 infection causes the disruption of structures in the cell 27 
nucleus termed PML nuclear domains or ND10, which contain promyelocytic 28 
leukaemia protein (PML) as a critical component. This disruption is achieved through 29 
the action of the viral E4 Orf3 protein, which forms track-like nuclear structures that 30 
associate with PML protein. This association is mediated by a direct interaction of 31 
Orf3 with a specific PML isoform, PMLII. We show here that the Orf3 interaction 32 
properties of PMLII are conferred by a 40 amino acid residue segment of the unique 33 
C-terminal domain of the protein. This segment was sufficient to confer interaction on 34 
a heterologous protein. The analysis was informed by prior application of a 35 
bioinformatic tool for the prediction of potential protein interaction sites within 36 
unstructured protein sequences (PONDR® analysis). This tool predicted three 37 
potential molecular recognition elements (MoRE) within the C-terminal domain of 38 
PMLII, one of which was found to form the core of the Orf3 interaction site thus 39 
demonstrating the utility of this approach. The sequence of the mapped Orf3 binding 40 
site on PML was found to be relatively poorly conserved across other species, 41 
however the overall organization of MoREs within unstructured sequence was 42 
retained, suggesting the potential for conservation of functional interactions. 43 
3 
Introduction 44 
Human adenovirus type 5 (Ad5) is one of a diverse collection of viruses that interact 45 
during infection with nuclear structures termed ND10 or PML nuclear domains (PML-46 
NDs (reviewed in Everett & Chelbi-Alix, 2007, Leppard & Dimmock, 2006). These 47 
structures are complex multiprotein assemblies within which promyelocytic leukaemia 48 
(PML) protein is a key component, essential for the localization of other proteins to 49 
PML-NDs. PML-NDs have been implicated in a variety of important cell processes, 50 
including DNA damage & stress responses, senescence, apoptosis and innate 51 
immunity (Bernardi & Pandolfi, 2007). 52 
 53 
The targeting of PML-NDs by viruses has been linked to avoidance of innate immune 54 
responses. The incoming genomes of several nucleus-replicating DNA viruses 55 
localize adjacent to PML-NDs (Ishov & Maul, 1996). For herpes simplex virus type 1 56 
(HSV1) this has been shown to involve the mobilization of existing PML-ND 57 
components to the sites of virus ingress (Everett & Murray, 2005). Both HSV1 and 58 
human cytomegalovirus infections induce the gross disruption of PML-NDs and, for 59 
HSV1, degradation of PML protein (Everett & Maul, 1994, Kelly et al., 1995). Ad5 60 
infection disrupts PML-NDs by deforming them into a large number of elongated 61 
tracks (Carvalho et al., 1995, Doucas et al., 1996). For both HSV1 and Ad5, 62 
mutations that prevent expression of the virus-coded PML-ND disruption function 63 
leave the viruses highly sensitive to innate and intrinsic antiviral responses (Everett 64 
et al., 2008, Everett et al., 2006, Ullman & Hearing, 2008, Ullman et al., 2007). Thus 65 
it has been proposed that PML-NDs or their components play a key role in the 66 
detection of virus infection and/or the subsequent cellular response and that 67 
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consequently many viruses have evolved proteins that target and modify this PML-68 
ND function. 69 
 70 
The pml gene encodes six C-terminally variant nuclear PML protein isoforms (I – VI) 71 
that contribute to PML-ND formation and these are further modified by covalent 72 
attachment of SUMO proteins to up to three lysine residues within their common N-73 
terminal domain (Fig. 1A) (Borden et al., 1996, Fagioli et al., 1992, Jensen et al., 74 
2001, Sternsdorf et al., 1997). Assembly of PML into PML-NDs requires the N-75 
terminal RBCC motif (Fig1A) (Borden et al., 1996) and is thought to be mediated by 76 
non-covalent binding of attached SUMO groups to an interaction motif encoded by 77 
exon 7a and present in isoforms I – V (Shen et al., 2006). The gene also encodes 78 
several cytoplasmic PML isoforms that lack the the nuclear localization signal 79 
because of exon-skipping during mRNA splicing which have unique functions 80 
(Salomoni & Bellodi, 2007). 81 
 82 
The Ad5 function that targets PML-NDs is the Orf3 protein, encoded by the E4 83 
transcription unit, which draws PML into co-localization with it in characteristic tracks 84 
(Carvalho et al., 1995, Doucas et al., 1996). This Orf3 function is conserved among 85 
diverse human adenoviruses (Evans & Hearing, 2003), unlike its ability to reorganise 86 
the DNA repair complex, MRN, which is specifically a feature of Orf3 from species C 87 
human Ads (Stracker et al., 2005). These two activities have been separated 88 
genetically. Recently, we showed that Orf3 targets PML-NDs via a specific and direct 89 
interaction with nuclear PML isoform II (Hoppe et al., 2006). Mutations in Orf3 that 90 
abrogated its ability to bind PMLII also eliminated its ability to rearrange PML-NDs.  91 
5 
The aim of the present study was to define the sequences within PMLII that were 92 
responsible for binding Orf3. To achieve this, a targeted deletion strategy was 93 
employed, informed by both homology comparisons between PMLII proteins from 94 
three species and also the application of a predictive bioinformatic tool for identifying 95 
potential protein interaction sites within amino acid sequences (PONDR®). From the 96 
properties of these mutant proteins, a 40 amino acid segment of the PMLII C-97 
terminus was found to be necessary and sufficient for Orf3 binding. The propensity of 98 
this region of PMLII for protein interactions was independently predicted by PONDR® 99 
analysis, demonstrating the utility of this approach to the mapping of protein : protein 100 
interactions. 101 
 102 
Methods 103 
Plasmid cloning and mutagenesis 104 
N-terminally FLAG-tagged PML cDNA clones in pCIneo expressing nuclear isoforms 105 
I - VI (Beech et al., 2005), and a Ad5 E4 Orf3 expression plasmid (Hoppe et al., 106 
2006), have been described previously. The PML ∆RBCC deletion links the N-107 
terminal FLAG epitope to PML residue 361, immediately distal to the RBCC motif. It 108 
was constructed by single-round PCR using FLAG-PML V template DNA with one 109 
primer bridging the FLAG-PML junction and the second complementary to PML exon 110 
5; a restriction fragment containing the deletion was then used to replace the 111 
equivalent fragment in each of the pCIFLAG-PML cDNA clones. Specific deletions in 112 
PMLII ∆RBCC were constructed by a two-stage PCR protocol using two common 113 
primers complementary to PML exon 6 and the vector distal to the cDNA insert, and 114 
pairs of mutagenic primers designed to fuse the coding sequence in frame at the 115 
desired location. Restriction fragments from second round PCR products were 116 
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substituted for the corresponding wild-type sequence encoding amino acids 555 to 117 
the C-terminus within PMLII ∆RBCC. To construct a GFP expression clone tagged 118 
with PMLII-derived sequences, plasmid phrGFP-N1 (Stratagene) was first modified to 119 
tag the hrGFP C-terminus with the SV40 large T antigen nuclear localization signal, 120 
GPKKKRKVG (Kalderon et al., 1984), and designated phrGFP-NLS. The sequence 121 
encoding PMLII amino acids 645-684 was amplified by PCR incorporating a BglII site 122 
at the N-terminal end and a stop codon plus EcoRI restriction site at the C-terminal 123 
end, suitable for cloning in-frame into phrGFP-NLS to generate phrGFP-NLS-m1m2. 124 
All clones were verified by DNA sequencing; primer sequences are available on 125 
request. 126 
 127 
Cells and transfection 128 
U2OS human osteosarcoma cells were maintained in McCoy’s 5A medium (Gibco) 129 
supplemented with 10% fetal bovine serum. Transfections of plasmid DNA were 130 
carried out using Lipofectamine2000 (Invitrogen), with DNA lipid complexes formed 131 
at a ratio of 2 µl/ 1 µg according to the manufacturer’s instructions. 132 
 133 
Immunofluorescence analysis 134 
2.5 x 105 cells were grown on coverslips in 12-well culture plates, transfected 24 hr 135 
later with 200 ng of PML plasmid plus either 200 ng Orf3 plasmid or empty vector, 136 
and 24 hr later fixed for 10 min with 10% formalin in phosphate-buffered saline (PBS) 137 
and permeabilized for 10 min with 0.5% Nonidet P40 in PBS. After blocking non-138 
specific protein interactions with PBS containing 1% w/v bovine serum albumin for 1 139 
hr, antigens were then detected by sequential 1 hr incubations with primary and 140 
secondary antibodies as follows: FLAG-tagged proteins, mouse monoclonal antibody 141 
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M2 (Sigma) and AlexaFluor488 goat-anti-mouse IgG (Invitrogen); endogenous PML, 142 
mouse monoclonal antibody PGM3 (Santa Cruz) and AlexaFluor488 goat-anti-mouse 143 
IgG (Invitrogen); Ad5 E4 Orf3, rat monoclonal antibody 6A11 (Nevels et al., 1999) 144 
and AlexaFluor546 goat-anti-rat IgG (Invitrogen). Bound antibodies or GFP were 145 
imaged using a Leica SP5 confocal microscope, and data exported as TIF images. 146 
All images presented are single z-sections through the centre of the nucleus. 147 
 148 
Co-immunoprecipitation and western blotting 149 
This was carried out as previously described (Hoppe et al., 2006). Briefly, 3.5 x 106 150 
U2OS cells plated on 10 cm dishes were transfected 24 hr later with 4 µg of PML 151 
plasmid or empty vector, together with 4 µg Orf3 plasmid. Cell extracts were 152 
prepared 24 hr later, a portion was reserved for total protein analysis and the 153 
remainder immunoprecipitated using covalently coupled FLAG-agarose (Sigma).  154 
Antigens were detected in western blot analysis using, for Orf3, rat monoclonal 155 
antibody 6A11 (Nevels et al., 1999) and, for FLAG-tagged PML, rabbit polyclonal 156 
anti-M2 (Sigma). 157 
 158 
Predictors of naturally disordered regions (PONDR®) analysis 159 
The PMLII sequence was analyzed for disorder propensity using the Predictor of 160 
Natural Disordered Regions VLXT (PONDR®) (Romero et al., 2001, Romero et al., 161 
1997) provided by Molecular Kinetics (Indianapolis, IN) and the VSL2 disorder 162 
predictor (Obradovic et al., 2006) via web access at http://www.pondr.com and 163 
http://www.ist.temple.edu/disprot/predictorVSL2.php, respectively. Regions with the 164 
potential to undergo disorder to order structural transitions upon binding to a partner, 165 
termed Molecular Recognition Elements (MoREs) (Oldfield et al., 2005) or Molecular 166 
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Recognition Features (MoRFs) (Mohan et al., 2006), are indicated by sharp 167 
downward spikes (order propensity) flanked by regions of disorder (PONDR scores > 168 
0.5). (PONDR® is copyright© 2004 by Molecular Kinetics, all rights reserved.) 169 
 170 
Pml gene homology alignments 171 
GenBank was searched for annotated PML genes and then for DNA sequences 172 
homologous to human pml exon 7a. This sequence was chosen as a search target 173 
because it encodes SUMO binding (Shen et al., 2006) and degron motifs (Scaglioni 174 
et al., 2006) that were likely to be well conserved between species. Full or partial pml 175 
gene sequences were identified from ten placental and one marsupial mammal 176 
species (Homo sapiens: NT_010194; Pan troglodytes: NW_001225242; Macaca 177 
mulatta: NW_001121176; Canis familiaris: NW_876294; Felis catus: 178 
AANG01142599; Mus musculus: NW_039474; Rattus norvegicus: NW_001084873; 179 
Bos taurus: NW_001494037; Equus caballus: NW_001799682; Sus scrofa: 180 
NW_001886480; Monodelphis domestica: NW_001581855). Sequences were 181 
manually aligned (MegAlign module, DNAStar), anchored on their homology to 182 
human exon 7a. In human pml, the 5’ end of exon 7b, which encodes the C-terminal 183 
259 residues of PMLII, lies 642 bp from the 3’ end of exon 7a. Splice acceptor sites 184 
and open reading frames (ORF) able to encode proteins with clear homology to 185 
human PMLII were found in very similar positions (636-674 bp from 7a) in seven 186 
cases. Of the remaining sequences, homology to the 5’ end of human exon 7b was 187 
found in mouse and rat (1332, 1171 bp from 7a) but the ORFs were scrambled by 188 
frame shifting mutations, while opossum had only a short intron from exon 7a to 8a 189 
(1966 bp compared with 7.5 – 10.7 kbp) with no discernable homology to exon 7b. 190 
Eight predicted exon 7b-encoded polypeptides were aligned using the ClustalV 191 
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method. This alignment introduced two 2-position gaps into the 259 residue human 192 
PMLII sequence. 193 
 194 
Results 195 
To show that the molecular target of E4 Orf3 within PML-NDs was PMLII, we 196 
previously co-expressed Orf3 with specific PML isoforms, in either co-197 
immunoprecipitation or immunofluorescence colocalization analysis (Hoppe et al., 198 
2006). For the latter approach, we employed PML-null primary mouse embryo 199 
fibroblasts, since similar analysis in human cells was complicated by the presence of 200 
endogenous PMLs with which the transfected PML isoform could hetero-oligomerize. 201 
In order to test the interaction of transiently expressed PML variants with Orf3 in 202 
PML-containing human cells in this study, advantage was taken of the observation 203 
that the RBCC motif within the common N-terminus of the nuclear PML isoforms (Fig. 204 
1A) is necessary for these proteins to participate in PML-ND formation (Fagioli et al., 205 
1998). FLAG-tagged PML I – VI lacking this motif were tested for their localization in 206 
U2OS cells either without or with coexpressed Orf3. All six ∆RBCC variants 207 
displayed an identical exclusively diffuse nuclear fluorescence when expressed alone, 208 
despite U2OS cells containing prominent PML-NDs formed of endogenous PML 209 
proteins (Fig. 1B, C and data not shown). This contrasts with the behaviour of the 210 
full-length isoforms, which are each recruited efficiently into PML-NDs (Beech et al., 211 
2005). When Orf3 was co-expressed with these proteins, only PMLII∆RBCC was 212 
relocalized into tracks with Orf3 (Fig. 1D, E and data not shown), as expected from 213 
the earlier study. This result further showed that residues 1-360 of PMLII were 214 
dispensable for its interaction with Orf3. 215 
 216 
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In order to further define the PML sequences involved in Orf3 binding, a set of four 217 
in-frame deletions (∆1-∆4) was constructed in the unique C-terminal domain of 218 
FLAG-PMLII∆RBCC. To inform the design of these deletions, three PMLII sequences 219 
annotated in GenBank databases, from human, chimpanzee and rhesus macaque, 220 
were compared. These sequences are highly conserved, but regions of lower 221 
conservation were identified and chosen as deletion end-points since these might be 222 
expected to lie between functional elements of the sequence (Fig. 2A). During 223 
construction of these mutations, we applied PONDR® analysis to further inform 224 
mutational planning. This method predicts protein interaction motifs in protein 225 
sequence, based on the observation that proteins that are capable of multiple 226 
interactions are frequently highly disordered and that within this disorder there are 227 
short sequences that are predicted to have a propensity to adopt ordered structure. 228 
Well-defined dips in VLXT disorder prediction curves within disordered regions 229 
(disorder scores > 0.5) can indicate short regions of order propensity (molecular 230 
recognition elements, MoRE) that undergo disorder-to-order transitions upon binding 231 
to a partner. Previous studies have validated the use of these distinctive downward 232 
spikes in VLXT prediction curves to locate functional binding regions (Oldfield et al., 233 
2005). The structural propensity of these short regions can be translated into stable 234 
structure by interaction with an interacting partner (Bourhis et al., 2004, Callaghan et 235 
al., 2004, Longhi et al., 2003). 236 
 237 
The unique C-terminal sequence of PMLII, from amino acid 571, was analysed by 238 
two PONDR® tools generating predictions VLXT and VSL2. The VLXT prediction 239 
(Fig. 2B) identified three potential MoREs within a region of predicted disorder that 240 
covered the entire PMLII C-terminal unique region, while the VSL2 prediction (which 241 
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is based on a different and larger set of known structured and unstructured proteins) 242 
showed MoREs 1 and 2 as part of a single region of increased order propensity (Fig. 243 
2C). By contrast, the PML I C-terminus was predicted to be more ordered with no 244 
MoREs (Fig. 2C), consistent with the fact that that this method of analysis is useful 245 
for finding sites of interaction within regions that are predominantly disordered but not 246 
within ordered regions. PMLII MoRE1 lay within the ∆1 mutation while MoRE3 was 247 
contained within ∆2; MoRE2 spanned the junction between ∆1 & ∆2. 248 
 249 
The ability of PMLII ∆RBCC variants ∆1- ∆4 to associate with Orf3 was assessed by 250 
fluorescence co-localization. All four mutated proteins showed diffuse nuclear 251 
fluorescence when expressed alone (Fig. 2D, F, H, J). When co-expressed with Orf3, 252 
∆3 and ∆4 showed complete co-localization in all cells (Fig. 2I, K) while ∆1 gave only 253 
diffuse nuclear fluorescence, lacking any colocalization ability (Fig. 2E). ∆2 showed 254 
an intermediate phenotype (Fig. 2G), with some cells demonstrating complete 255 
colocalization (Fig. 2G inset) while the majority showed some colocalized tracks but 256 
with considerable residual diffuse nuclear fluorescence, suggesting that the ability of 257 
∆2 to bind to Orf3 was impaired but not completely abrogated. Thus, PML residues 258 
615-684, including MoRE1 and part of MoRE2, are necessary for Orf3 binding while 259 
sequences C-terminal of residue 685, including MoRE3, are not essential. 260 
 261 
To map more precisely the sequences of PMLII necessary for the Orf3 interaction, 262 
and in the light of the PONDR® predictions (Fig. 2B, C), five further in-frame 263 
deletions were constructed in the PMLII C-terminus (Fig. 3A), removing either 264 
subsections of the region deleted in ∆1 (∆7, ∆8, ∆m1), or the MoRE2 motif 265 
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overlapping the boundary of ∆1 and ∆2 (∆m2); ∆m1 & ∆m2 were also combined in a 266 
double mutant (∆m1m2). When tested in the fluorescence co-localization assay, ∆8 267 
and ∆m2 strongly associated with Orf3 tracks (Fig. 3B, E) while ∆m1, ∆7 and ∆m1m2 268 
were essentially unable to do so (Fig. 3C, D and data not shown); faint tracks of ∆7 269 
were sometimes seen, but in contrast to ∆8 and ∆m2 these only partially co-localized 270 
with Orf3. These data mapped the Orf3 interaction motif in PMLII to residues 645-674, 271 
with a possible supporting involvement of adjacent sequences from the properties of 272 
mutant ∆2 (Fig. 2G). This mapped region coincides almost exactly with the region of 273 
potential induced order (MoRE1/2) predicted in PMLII by PONDR® VLXT and VSL2 274 
(Fig. 2B, C). 275 
 276 
To confirm that the induction of PML variant localization into Orf3-colocalized tracks 277 
was an indication of protein : protein interaction between these two partners, co-278 
immunoprecipitation analysis was performed (Fig. 4). Each of the PML variants 279 
tested was efficiently expressed and precipitated by anti-FLAG agarose beads (Fig. 280 
4A). However, although expression of Orf3 in the extracts was broadly equivalent 281 
across all samples (Fig. 4B), the amounts of Orf3 co-precipitated with the various 282 
FLAG-PMLs varied greatly (Fig. 4C). As expected, II ∆RBCC co-precipitated 283 
significant amounts of Orf3 (lane 4) while I ∆RBCC, included as a negative control, 284 
did not (lane 3). The ∆1, ∆m1, ∆m1m2 and ∆7 variants of II ∆RBCC did not co-285 
precipitate Orf3 at all (lanes 5, 9, 11, 12), consistent with the fact that these variants 286 
also failed to relocalize into tracks when coexpressed with Orf3 (Figs. 2, 3 and data 287 
not shown). The other variants tested: ∆2, ∆3, ∆4, ∆8 and ∆m2, each of which was 288 
able to associate with Orf3 by fluorescence analysis, also co-precipitated Orf3, in the 289 
case of ∆3 & ∆4 more efficiently than did the wild-type sequence. These results 290 
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therefore confirm that PMLII residues 645-674, comprising the sequence deleted in 291 
∆m1 plus ∆7, are required for Orf3 binding. 292 
 293 
To determine if these essential sequences from PMLII were also sufficient for Orf3 294 
binding, PMLII residues 645-684, comprising MoRE1 and sequences C-terminal to it 295 
up to the original ∆1 boundary within MoRE2, were transferred onto the C-terminus 296 
of hrGFP that was tagged with the nuclear localization signal from SV40 large T 297 
antigen to direct the protein to the nucleus; as expected, the location of this protein 298 
was unaffected by co-expression of Orf3 (Fig. 5A). Addition of the PMLII sequences 299 
caused the hrGFP fusion, expressed alone, to quantitatively relocalize into structures 300 
that had the appearance of nucleoli (Fig. 5B). However, when Orf3 was co-expressed 301 
with this construct, a substantial fraction of the fusion protein was drawn back out of 302 
these structures into co-localization with Orf3 tracks (Fig. 5C), indicating that PMLII 303 
residues 645-684 were sufficient for Orf3 interaction and could function 304 
autonomously from the rest of the protein. 305 
 306 
Having defined the Orf3-binding element in PMLII, we were interested to determine 307 
whether either its amino acid sequence or the position of MoREs within it was 308 
conserved among the PML proteins of different species. Seven of ten PML genes 309 
identified in database searches could be predicted to encode homologues of human 310 
PMLII. Of the other three, the exon 7b sequences in mouse and rat were non-311 
functional, in agreement with experimental data for the mouse (Condemine et al., 312 
2006), while the opossum sequence lacked exon 7b completely. The extent of 313 
homology at each position in an alignment of human PMLII with these seven 314 
predicted PMLII C-terminal domains is represented in Fig. 6A. Only 27% of 263 315 
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positions were identical across seven or all eight of the sequences. This compares 316 
with 63% of 267 positions in a similar alignment of predicted PML I C-terminal 317 
domains (substituting murine PML for feline PML sequence, since the feline exon 9 318 
sequence was not available; data not shown). Thus the unique sequences of PMLII 319 
that are targeted by Ad5 are relatively poorly conserved in PML. Moreover, the 320 
mapped Orf3 interaction sequence in PMLII did not coincide with the region of 321 
highest conservation (Fig. 6A, arrow). 322 
 323 
PONDR® VLXT analyses were then run for the predicted bovine (Fig. 6B) and canine 324 
(Fig. 6C) PMLII C-termini. Despite the low sequence identity between the bovine and 325 
human sequences (45% of 244 aligned positions where both have residues), three 326 
MoREs were predicted in bovine PMLII at positions very similar to those identified in 327 
the human protein. The canine PMLII exon 7b-encoded sequence is significantly 328 
shorter than the human form, being truncated at position 210 in the alignment. It too 329 
was predicted to contain several potential protein interaction sites, although their 330 
precise positions differed from those predicted for the human and bovine PMLII 331 
MoREs. 332 
 333 
Discussion 334 
The Ad5 E4 Orf3 protein is required for the disruption of PML-NDs. This Orf3 function 335 
requires it to interact with PML isoform II (Hoppe et al., 2006), a major component 336 
within the population of PML species in the cell (Condemine et al., 2006). In this 337 
study, we have shown that the target for Orf3 binding is a 40 residue sequence within 338 
PMLII. Deletion of this sequence destroys the interaction with Orf3 whilst its transfer 339 
to a heterologous protein confers Orf3 interaction properties in an in vivo assay. The 340 
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interacting PML sequence, residues 645-684, is encoded by exon 7b of the pml gene 341 
and is thus unique to PMLII among nuclear PML species, in full agreement with the 342 
observation that only this PML isoform can interact with Orf3.  343 
 344 
The Orf3 binding sequence of PMLII was defined using cDNA clones deleted for the 345 
RBCC motif. The encoded proteins therefore lack the ability to heteroligomerize 346 
(Peng et al., 2002) and so cannot be indirectly recruited into association with Orf3 via 347 
PML:PML interactions. As expected, they completely failed to localize into PML-NDs 348 
(Borden et al., 1996), even though this cell type contained clearly defined PML-ND 349 
structures formed of endogenous PML with which the heterologous proteins were 350 
free to interact. Among the six nuclear PML isoforms, only the PMLII ∆RBCC 351 
derivative could associate with Orf3 in immunofluorescence or co-352 
immunoprecipitation assays, in agreement with our previous study using full-length 353 
PMLII (Hoppe et al., 2006) and indicating that the association of PMLII with PML-NDs 354 
is not necessary for its interaction with Orf3.  355 
 356 
The various deletion variants of PMLII that retained Orf3 interaction ability did not 357 
always appear equivalent in activity. Although the fluorescence co-localization assay 358 
is not quantitative, it was consistently observed that the ∆3 and ∆4 mutants were 359 
very effectively brought into Orf3 tracks as compared with the ∆2 mutant and even 360 
the undeleted PMLII C-terminus. These same proteins were also more effective in 361 
co-precipitating Orf3. These data suggest that the C-terminal 70 residues of PMLII 362 
may exert a negative effect on its binding to Orf3. The other mutants that retained 363 
Orf3 interaction function, ∆2, ∆8 and ∆m2, all appeared to be less efficiently recruited 364 
to Orf3 tracks, and for ∆8 and ∆m2 this was supported by reduced co-365 
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immunoprecipitation of Orf3. Thus the activity of the core Orf3 binding element in 366 
PMLII may be enhanced by its flanking sequences. 367 
 368 
The use of deleted protein variants to map protein interactions has the caveat that 369 
such deletions may cause gross changes to the structure of the folded protein and 370 
hence impact on functions that are actually encoded elsewhere in the polypeptide. All 371 
of the C-terminally deleted PMLII variants used in the study accumulated to similar 372 
levels to undeleted PMLII, as judged by the strength of bands in western blot analysis 373 
of total protein and the typical fluorescent intensity of individual expressing cells 374 
examined by immunofluorescence. Both these observations indicate that the deleted 375 
PMLII species were not destabilised relative to full length protein and hence are not 376 
likely to be grossly altered in structure. The ability to express deleted forms of PMLII 377 
without such problems being manifest is likely due to the predicted disordered nature 378 
of the entire C-terminal domain. 379 
 380 
The addition of the Orf3 interaction motif of PMLII onto hrGFP conferred apparent 381 
nucleolar targeting on the protein. PML has been shown previously to be induced into 382 
nucleolar localization by either DNA damage or inhibition of the proteasome 383 
(Bernardi et al., 2004, Mattsson et al., 2001) or to associate with nucleoli during 384 
normal growth of non-transformed cells (Janderovd-Rossmeislova et al., 2007). It is 385 
conceivable that our study has identified an element that contributes to this nucleolar 386 
targeting of endogenous PML proteins. However, it was shown recently that direct 387 
nucleolar targeting of PML was largely restricted to PML isoforms I and IV 388 
(Condemine et al., 2007). Hence it is more probable that the nucleolar localization of 389 
17 
hrGFP-M1M2 protein observed here results from the generation of activity through 390 
the transfer of this protein sequence into a heterologous context. 391 
 392 
Orf3 reorganizes several cellular proteins in addition to PML, including RBCC family 393 
member TIF1α, which directly binds Orf3 (Yondola & Hearing, 2007), and the MRN 394 
complex comprising Mre11, Rad50, and Nbs1 (Stracker et al., 2002). The direct 395 
binding partner for Orf3 within MRN has not been determined, although Nbs1 is 396 
dispensable for Orf3 to relocalize Rad50 and Mre11 (Araujo et al., 2005). The Orf3 397 
sequence requirements for interaction with PML, MRN and TIF1α are very similar, 398 
suggesting that the Orf3-interaction sites in these proteins might be sequence-related. 399 
Homology matches to the 40 residue Orf3-interaction motif from PMLII were 400 
identified in both Rad50 and TIF1α (Fig. 7). The significance of the Rad50 match is 401 
unclear, but the TIF1α match is clearly better than achieved in comparisons with two 402 
irrelevant proteins of similar length (T antigen, L4 100K). Moreover, the sequence 403 
match lies at the C-terminal end of the TIF1α RBCC domain, which has been shown 404 
to mediate Orf3 binding (Yondola & Hearing, 2007). Finally, the corresponding 405 
sequence from its Orf3 non-interacting relative TIF1β (Yondola & Hearing, 2007) is 406 
significantly less similar to the PMLII Orf3 binding motif (Fig. 7). These strands of 407 
argument support the possibility that sequence relatedness with PMLII can predict 408 
the Orf3 binding site in TIF1α. 409 
 410 
In addition to forming nuclear tracks, Orf3 also localizes to perinuclear cytoplasmic 411 
structures identified as aggresomes (Araujo et al., 2005) and participates in 412 
delivering MRN complex to these structures for inactivation and degradation (Araujo 413 
et al., 2005, Liu et al., 2005). Here, Orf3 aggresomes were observed in only a 414 
18 
minority of expressing cells. PML species unable to bind Orf3 never co-localized in 415 
these structures (e.g. Fig. 1D) while those variants able to bind Orf3 associated with 416 
aggresomes only in a few cells expressing high levels of the PML construct (data not 417 
shown). These data are consistent with the report that endogenous PML does not 418 
localize with Orf3 in aggresomes (Araujo et al., 2005). 419 
 420 
The mapped binding site for Orf3 in PMLII was found to be relatively poorly 421 
conserved between PML proteins of different species. Exon 7b, which encodes the 422 
unique portion of PMLII, was only found intact in a subset of species for which data 423 
was available, and for those species able to encode PMLII, its isoform-specific C-424 
terminal sequence was considerably less well conserved than the equivalent region 425 
of PML I. Moreover, even within the PMLII C-terminus, the mapped interaction site 426 
was not the most conserved part of the sequence. These findings suggest that Ad5 427 
Orf3 may not be able to interact widely with the PML proteins of other species. 428 
However, both the two non-human PMLII sequences for which PONDR® analysis 429 
was carried out were predicted to contain MoREs and, for the bovine sequence, the 430 
position of these predicted elements was very similar to those predicted for human 431 
PMLII. Thus, it may be that Orf3 recognizes a shape or structure in PML rather than 432 
a highly specific sequence, in which case it may have wider cross-species binding 433 
reactivity than the sequence homology analysis suggests. Whether Ad5 Orf3 can 434 
bind specifically to PMLII from other species remains to be tested. 435 
 436 
Adenoviruses have been isolated from a wide range of animal species. Whilst these 437 
viruses retain the overall genome organization of the human Ads, including a 438 
presumptive E4 gene at the genome right end with multiple open reading frames, 439 
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outside of the simian Ads it is not possible to identify definitive functional homologues 440 
of human Ad E4 Orf3 by sequence comparison. Thus, the host target(s) of Orf3 might 441 
be expected also to be quite divergent, assuming function has been conserved 442 
during the co-evolution of these viruses with their respective hosts. Given that the 443 
disruption of PML-NDs by Orf3 combats an intrinsic or innate antiviral response in 444 
human and primate cells (Ullman & Hearing, 2008, Ullman et al., 2007), it will be 445 
interesting to explore the function of Ad5 Orf3 in other host species. 446 
 447 
PONDR® analysis identified three potential protein interaction sites (MoREs) within 448 
the C-terminal domain of human PMLII, one of which (MoRE1) formed the core of the 449 
Orf3-binding sequence subsequently identified. This study therefore demonstrates 450 
the potential for predicting functional protein binding sites within unstructured 451 
polypeptide sequence by this method. The MoRE1 motif is unlikely to have evolved 452 
within PMLII to provide an interaction site for Orf3, given that the ability of the virus to 453 
make this interaction with the host can be seen as favouring the replication of virus 454 
and hence is likely to be deleterious to the host. Instead, it and the other two 455 
predicted MoREs are likely to have one or more endogenous cellular partners. The 456 
experimentally demonstrated ability of the C-terminal MoRE of p53 to bind four 457 
different partners (Oldfield et al., 2008) serves as a model for how a viral protein 458 
could usurp an endogenous MoRE-mediated binding interaction and thereby alter 459 
normal cellular communication or protein function. Although MoREs do exhibit 460 
different degrees of specificity, their minimal binding determinants facilitate 461 
promiscuity. If MoRE1 does have an endogenous partner, then its displacement by 462 
Ad5 Orf3 could contribute to the observed phenotype in relieving the antiviral 463 
response or to additional, as yet undetermined, phenotypes. 464 
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 619 
Figure Legends 620 
Figure 1. PMLII – Orf3 interaction does not require the RBCC motif. Panel A: A 621 
schematic representation of PMLII (top) and its ∆RBCC variant (bottom). The RBCC 622 
domain comprises Ring Finger (R), two zinc-binding B boxes (B) and a Coiled Coil 623 
region (CC). Also indicated are the PML nuclear localisation signal (N), SUMO 624 
binding site (S) and the three sites of covalent modification by SUMO1 (Su). The 625 
FLAG epitope N-terminal extension is shown as a black box. Panels B – F: 626 
Immunofluorescence analysis of U2OS cells either transfected with (B) FLAG-PML I 627 
∆RBCC or (C) FLAG-PMLII ∆RBCC and stained for FLAG (green) and DNA (DAPI, 628 
blue), transfected with (D) FLAG-PML I ∆RBCC & Orf3 or (E) FLAG-PMLII ∆RBCC 629 
and Orf3 and stained for FLAG (green) and Orf3 (red), or mock-transfected (F) and 630 
stained for endogenous PML (green) and DNA (DAPI, blue). Scale bars,– 10 µm. 631 
 632 
Figure 2.  Delineation of the Orf3 binding site in the C-terminus of PMLII. (A) Amino 633 
acid sequence alignment of the exon 7b sequences of PMLII from human (Hom), 634 
chimpanzee (Pan) and Macaque (Mac); grey shaded regions indicate identity 635 
27 
between the three sequences. The beginning and end points of the in-frame deletion 636 
mutations ∆1 – ∆4 generated in human PMLII cDNA are indicated below the 637 
alignment. (B) PONDR®  VLXT prediction for the C-terminal domain of PMLII, 638 
showing the predicted molecular recognition elements (MoRE) 1 - 3 relative to 639 
mutations ∆1 – ∆4. (C) PONDR® VLS2 prediction for the C-terminal domain of PMLII 640 
(grey) and PML I (black). Panels D – K: Immunofluorescence analysis of U2OS cells 641 
transfected with (D) FLAG-PMLII∆1 alone or (E) with Orf3, (F) FLAG-PMLII∆2 alone 642 
or (G) with Orf3, (H) FLAG-PMLII∆3 alone or (I) with Orf3, (J) FLAG-PMLII∆4 alone 643 
or (K) with Orf3, and stained for FLAG and Orf 3. Scale bar, panel D – 10 µm; all 644 
panels at this magnification. 645 
 646 
Figure 3. Co-localization of PMLII with Orf3 requires sequences from MoRE1. (A) 647 
PMLII sequence across the MoRE1 & MoRE2 elements, showing the positions of 648 
deletion mutations as indicated. Panels B – E:  Immunofluorescence analysis of 649 
U2OS cells transfected with Orf3 plus (B) PMLII∆8, (C) PMLII∆m1, (D) PMLII∆7, (E) 650 
PMLII∆m2. Orf3 staining is shown on the left and FLAG (PML) staining on the right in 651 
each panel. Scale bar, panel B – 10 µm; all panels at this magnification. 652 
 653 
Figure 4. Interaction of PMLII sequence variants with Orf3 by co-immunoprecipitation 654 
analysis. U2OS cells were co-transfected with Orf3 and FLAG-PML expression 655 
plasmids as indicated at the top of the figure and cell extracts prepared for total 656 
protein analysis and immunoprecipitation with anti-FLAG antibody. (A) 657 
Immunoprecipitated FLAG-PML; (B) Orf3 in total extract; (C) Orf3 co-658 
immunoprecipitated with FLAG-PML. The migration positions of protein molecular 659 
mass markers (kD) are shown at the right of each panel. 660 
28 
 661 
Figure 5. PMLII residues 645-684 are sufficient for Orf3 binding. U2OS cells were 662 
transfected with (A) hrGFP-NLS plus Orf3, (B) hrGFP-NLS-m1m2 plus empty vector 663 
or (C) hrGFP-NLS-m1m2 plus Orf3 and then stained for Orf3 (red) and DNA (DAPI, 664 
blue). GFP fluorescence was visualised directly (green). Scale bar – 10 µm. 665 
 666 
Figure 6. Sequence and structure conservation in PMLII. (A) Sequence conservation 667 
across the predicted pml exon7b-encoded polypeptides from human, chimpanzee, 668 
macaque, dog, cat, cow, horse and pig (see Methods for details). The bar height and 669 
shading indicate the extent of homology at each position in the alignment, with the 670 
maximum bar height shown representing identity across all eight sequences and the 671 
next highest representing seven out of eight identity. The position of the 40 residue 672 
Orf3-binding sequence is represented by a black arrow. (B and C) PONDR®  VLXT 673 
predictions for the predicted C-terminal domains of bovine (B) and canine (C) PMLII. 674 
 675 
Figure 7.  Homology alignments of the PMLII Orf3 binding motif with other proteins. 676 
Protein sequences (GenBank: AAB07119 [Rad50]; NP_005582 [Mre11]; NP_056989 677 
[TIF1α]; CAA66150 [TIF1β]) were analysed in pairwise alignments with the 40 678 
residue Orf3 binding motif from PMLII (residues 645-684) using the Lipman-Pearson 679 
method, DNAStar software (Ktuple 2; Gap Penalty 4; Gap Length Penalty 12). 680 
Symbols “| : . “ indicate identity and decreasing levels of similarity between each 681 
sequence and the PMLII motif. 682 
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Figure 7
Rad50 (1312aa):   901 LYREI-KDAK-EQVSPLETTLEK 921
|||.  :. :  :  .|:. |::
PMLII: HQERPAVHRGIRYLLYRAQ-RAIRLRHALRLHPQLHRAPIR
|||. :  : |||| ||
TIF1α (1050aa): 375 LLYSKRLITYRLRHLLR 391
||:.       :|::||
TIF1β (835aa):   361 LLLSKKLIYFQLHRALK 377
|||:
SV40 large T:    170 LLYK 173   (708aa)
||: :.: ||::
Ad5 L4 100K:        189 RAD-KQLALRQG 199 (807aa) 
